- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06421610
OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion.
Implementation and Evaluation of Pressurized Intrathoracic Aerosol Chemotherapy (PITAC) for the Treatment of Patients With Malignant Pleural Effusion. A Danish Phase I Study (OPC5 Study)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a safety and feasibility study of repeated (minimum two procedures) PITAC directed treatments, and the primary outcome is the number of patients with medical adverse events (AEs) according to the Common Terminology Criteria for Adverse Events (CTCAE) and/or surgical complications according to the Clavien-Dindo classification. This study will include consecutive MPE patients until 20 patients have completed at least two PITAC´s. The PITAC directed treatment will be performed in 4 week intervals. Bedside ultrasound, VAS-pain and VAS-breathlessness, and Quality of Life questionnaires will be performed at baseline, one month follow-up and three months follow-up.
Patients with MPE who are eligible for surgery are identified during the multidisciplinary tumor (MDT) conference at the Department of Surgery, Odense University Hospital (OUH), and included based on predefined in- and exclusion criteria. Patients with MPE from non-colorectal or -appendix cancer will be treated with a combination of cisplatin and doxorubicin. Patients with MPE from colorectal or appendix cancer will be treated with oxaliplatin.
In brief, The PITAC procedure is the application of aerosolized chemotherapy into the pleural cavity using thoracoscopy. PITAC is performed in the prone or lateral position. A double lumen endotracheal tube is used to allow exclusion of the ipsilateral lung, but this is not (always) necessary with the patient in the prone position. The first trocar is placed guided by ultrasound, and after safe positioning a second trocar can be inserted guided by video thoracoscopy. The chemotherapy is applied to the pleural cavity through a nebulizer inserted through one of the trocars and linked to a high-pressure injector. After five minutes the chemotherapy has been delivered to the pleural cavity, and after an additional 30 minutes of simple diffusion, the intrathoracic air saturated with chemotherapy is evacuated through a series of filters.
The patients are monitored for a minimum of one day and will after each PITAC directed treatment be screened for adverse events.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Pernille Schjødt Hansen, Student
- Phone Number: +45 65411857
- Email: pernille.schjodt.hansen@rsyd.dk
Study Locations
-
-
-
Odense, Denmark, 5000
- Recruiting
- Odense PIPAC Center, Department of Surgery, Odense University Hospital
-
Contact:
- Martin Graversen, MD
- Phone Number: +45 30549497
- Email: martin.graversen@rsyd.dk
-
Principal Investigator:
- Martin Graversen, MD, Ph.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Symptomatic MPE visible with bedside ultrasound
- Histologically or cytologically verified malignancy
- Status CT-scan not older than four weeks
- MPE requiring at least one drainage procedure
- Drained ≥ 14 days before the first PITAC directed treatment
- Bidirectional systemic chemotherapy or immunotherapy ≥ 14 days before the first PITAC directed treatment or no simultaneous systemic chemotherapy or immunotherapy
- ECOG Performance status 0-2
- Life expectancy ≥ 3 months
- Age ≥ 18 years
- Danish-speaking and reading patients
- Written informed consent according to the local Ethics Committee requirements
Exclusion Criteria:
- A history of allergic reaction to cisplatin or other platinum containing compounds or doxorubicin
- Renal impairment, defined as GFR < 40 ml/min (Cockcroft-Gault Equation)
- Myocardial insufficiency, defined as NYHA class > 2
- Impaired liver function defined as bilirubin ≥1.5
Fertility, pregnancy and lactation: Female subjects will be considered of non-reproductive potential if they are either a, b or c:
- postmenopausal (defined as at least 12 months with no menses without an alternative medical cause; in women < 45 years of age a high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. In the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.
- have had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy or bilateral tubal ligation/occlusion, at least 6 weeks prior to screening.
- have a congenital or acquired condition that prevents childbearing. Previous intrathoracic chemotherapy, intrathoracic antibody treatment or chemical pleurodesis
- Any other condition or therapy, which in the investigator´s opinion may pose a risk to the patient or interfere with the study objects
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PITAC
Malignant Pleural Effusion (MPE) from colorectal or appendix cancer will be treated with Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) using oxaliplatin 92 mg/m2 in 150 ml dextrose. MPE from non-colorectal or -appendix cancer will be treated with PITAC using cisplatin 10.5 mg/m2 in 150 ml saline and 2.1 mg/m2 in 50 ml saline. PITAC is performed with a intrapleural pressure of 12 mmHg and the aerosolised chemotherapy will be nebulized at a maximum pressure of 300 PSI and a flow-rate of 0.5-1.8 ml/min. The PITAC directed treatment will be planned with 4 week intervals and patients may receive bi-directional systemic chemotherapy simultaneously. |
Cisplatin, oxaliplatin and doxorubicin are standard, commercially available intravenous cytostatic drugs in oncologic treatment with alkylating and topoisomerase inhibitor effect, respectively.
Based on the available data and experience from 11 PITAC procedures at OPC, PITAC with cisplatin, oxaliplatin and doxorubicin for intrapleural administration is expected to be well tolerated with a minimal of nausea, subcutaneous emphysema and transient chest pains.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Medical adverse events
Time Frame: 30 days from PITAC directed treatment
|
Number of patients with medical adverse events (AEs) according to the Common Terminology Criteria for Adverse Events (CTCAE) version 6.0 defined as CTCAE ≥ 4 within 30 days after the procedure.
|
30 days from PITAC directed treatment
|
Surgical complications
Time Frame: 30 days from PITAC directed treatment
|
Number of patients with surgical complications according to the Clavien-Dindo classification defined as Clavien-Dindo ≥ 3b within 30 days after the procedure.
|
30 days from PITAC directed treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients completing three PITAC treatments
Time Frame: 12 months
|
To evaluate the number of patients completing three PITAC treatments
|
12 months
|
Extent of visible pleural metastasis
Time Frame: 12 months
|
To macroscopically evaluate the extent of visible pleural metastasis (PLM) during PITAC directed therapy via the new PLM-score based on size of lesions (LS). LS 0 No tumor seen LS1 Tumor up to 0.5 cm LS2 Tumor up to 5.0 cm LS3 Tumor > 5.0 cm or confluence |
12 months
|
Pathology on pleural metastasis biopsies
Time Frame: 12 months
|
To evaluate Pleural Regression Grade Score (Ple-RGS) in biopsies from visible pleural metastasis Ple-RGS is a modification of the Peritoneal Regression Grading score (PRGS).
Ple-RGS 1: Complete histological response Ple-RGS 2: Regressive changes are predominant over cancer cells (major response) Ple-RGS 3: Cancer cells are predominant over regressive changes (minor response) Ple-RGS 4: No response
|
12 months
|
Cytology on malignant pleural effusion fluid
Time Frame: 12 months
|
To evaluate cytology on MPE during PITAC directed therapy.
The cells will be graded according to a five-tiered score: malignant cells, suspicious cells, atypical cells, no malignant cells and other
|
12 months
|
LENT score
Time Frame: 12 months
|
To evaluate the LENT score after each PITAC directed therapy.
Low risk: 0-1 Moderate risk: 2-4 High risk: 5-7
|
12 months
|
Length of Stay (LOS)
Time Frame: 12 months
|
Quantify the length of stay (LOS) (surgery = day 0)
|
12 months
|
Personnel safety (environmental)
Time Frame: 12 months
|
Assess personnel safety by measuring of platinum traces in the operating room.
|
12 months
|
Personnel safety (biological)
Time Frame: 12 months
|
Assess personnel safety by measuring of platinum traces in blood samples from surgeons and/or OR nurses.
|
12 months
|
Lung function evaluation by SAT
Time Frame: 12 months
|
To evaluate lung function by saturation (SAT) before PITAC directed treatment (day 0) and at discharge (day 1), day 30 and 3 months after the last PITAC directed treatment
|
12 months
|
Breathlessness
Time Frame: 12 months
|
To evaluate breathlessness using visual analogue scales (VAS-breath) before PITAC directed treatment (day 0) and at discharge (day 1), day 30, and 3 months after the last PITAC directed treatment
|
12 months
|
Pain assessment
Time Frame: 12 months
|
To evaluate pain using visual analogue scales (VAS-pain) before PITAC directed treatment (day 0) and at discharge (day 1), day 30, and 3 months after the last PITAC directed treatment
|
12 months
|
Quality of Life questionnaires
Time Frame: 12 months
|
To evaluate the quality of life with EORTC-QLQ-C30 at baseline, day 30 and 3 months after the last PITAC directed treatment
|
12 months
|
Change in MPE volume
Time Frame: 12 months
|
To calculate the change in volume of drained MPE from 2 months before the first PITAC treatment to three months after the last PITAC treatment
|
12 months
|
Long term complications
Time Frame: 12 months
|
To assess long-term complications 3 months after the third PITAC directed treatment
|
12 months
|
Survival
Time Frame: 12 months
|
Median overall survival
|
12 months
|
Lung function evaluation by FEV1
Time Frame: 12 months
|
To evaluate lung function by Forced Expired Volume in the first second (FEV1) before PITAC directed treatment (day 0) and at discharge (day 1), day 30 and 3 months after the last PITAC directed treatment
|
12 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PITAC-OPC5
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Quality of Life
-
Assiut UniversityUnknownImproving Quality of LifeEgypt
-
Children's National Research InstituteRecruitingProfessional Quality of LifeUnited States
-
Istituto Ortopedico RizzoliUniversity of BolognaActive, not recruitingImprove Quality of LifeItaly
-
B. Braun Medical SAUnknownQuality of Life of Colostomized Patient
-
Mattu UniversityCompletedBreif Description: Patients' Quality of Life ofEthiopia
-
University of South CarolinaNational Institute on Minority Health and Health Disparities (NIMHD)RecruitingHealth Related Quality of LifeUnited States
-
PharmanexSprim Advanced Life SciencesCompletedHealth-related Quality of LifeUnited States
-
Linkoeping UniversityRecruiting
-
South Valley UniversityActive, not recruitingDeterminants of Health-related Quality of Life for Patients After Renal Lithotripsy: PNL Versus RIRSHealth Related Quality of LifeEgypt
-
Region VästmanlandUnknownHealth Related Quality of Life
Clinical Trials on PITAC
-
Sabine RhodeRuhr University of BochumUnknownGastric Cancer | Colorectal Cancer | Ovarian Cancer | Ascites | Pseudomyxoma Peritonei | Pancreas Cancer | Chemotherapeutic Toxicity | Pleural Effusion | Gallbladder Cancer | CUP | Appendix Cancer | Pleural Mesothelioma | Peritoneum Cancer | Peritoneum Neoplasm | Pleural CancerSingapore, France, Germany, Australia, Argentina, Austria, Belgium, Denmark, Italy, Poland, Russian Federation, Spain, Switzerland